EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors

Radu A Paun, Sarah Jurchuk, Maryam Tabrizian iD

Bioengineering & Translational Medicine · 2024-03 · 9 (2)

DOI: 10.1002/btm2.10601 ↗

At a glance

Übersichtsarbeit in Bioengineering & Translational Medicine, published online on 2023-11-09. Written by Radu A Paun and 2 co-authors. Institution: Department of Biomedical Engineering, Faculty of Medicine and Health Sciences McGill University Montreal Quebec Canada. Cited 40 times so far (Crossref); 298 references. The full text is freely available (open access, CC BY 4.0). Funded by: Canadian Institutes of Health Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Lipid nanoparticles (LNPs) are biocompatible drug delivery systems that have found numerous applications in medicine. Their versatile nature enables the encapsulation and targeting of various types of medically relevant molecular cargo, including oligonucleotides, proteins, and small molecules for the treatment of diseases, such as cancer. Cancers that form solid tumors are particularly relevant for LNP‐based therapeutics due to the enhanced permeation and retention effect that allows nanoparticles to accumulate within the tumor tissue. Additionally, LNPs can be formulated for both locoregional and systemic delivery depending on the tumor type and stage. To date, LNPs have been used extensively in the clinic to reduce systemic toxicity and improve outcomes in cancer patients by encapsulating chemotherapeutic drugs. Next‐generation lipid nanoparticles are currently being developed to expand their use in gene therapy and immunotherapy, as well as to enable the co‐encapsulation of multiple drugs in a single system. Other developments include the design of targeted LNPs to specific cells and tissues, and triggerable release systems to control cargo delivery at the tumor site. This review paper highlights recent developments in LNP drug delivery formulations and focuses on the treatment of solid tumors, while also discussing some of their current translational limitations and potential opportunities in the field.

Subjects

Author keywords

chemotherapydrug combinationgene therapyimmunotherapylipid nanoparticlessolid tumorstranslational limitations

Authors and institutions

  • Department of Biomedical Engineering, Faculty of Medicine and Health Sciences McGill University Montreal Quebec Canada.
  • Faculty of Dentistry and Oral Health Sciences McGill University Montreal Quebec Canada.

ORCID profiles: Maryam Tabrizian

Funding

  • Canadian Institutes of Health Research

Cite

APA

Paun, R. A., Jurchuk, S., & Tabrizian, M. (2024). A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors. Bioengineering & Translational Medicine, 9(2). https://doi.org/10.1002/btm2.10601

Vancouver

Paun RA, Jurchuk S, Tabrizian M. A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors. Bioengineering & Translational Medicine. 2024;9(2). doi:10.1002/btm2.10601

BibTeX
@article{Paun2024,
  author = {Paun, Radu A and Jurchuk, Sarah and Tabrizian, Maryam},
  title = {A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors},
  journal = {Bioengineering & Translational Medicine},
  year = {2024},
  volume = {9},
  number = {2},
  doi = {10.1002/btm2.10601}
}
Start for free →